Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 6/20 | 0.34 |
| ▸ | PDE4A | P27815 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 11/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 10/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 9/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL127763 | 0.94 | PDE4D (0.35) | PDE4DPDE4APDE4BPDE4CTLR7 | |
| SCHEMBL127272 | 0.93 | PDE4D (0.33) | PDE4DPDE4APDE4BPDE4CTLR7 | |
| SCHEMBL127470 | 0.92 | PDE4D (0.34) | PDE4DPDE4APDE4BPDE4CTLR7 | |
| SCHEMBL129219 | 0.92 | PDE4D (0.34) | PDE4DPDE4APDE4BPDE4CTLR7 | |
| SCHEMBL128716 | 0.92 | PDE4D (0.32) | PDE4DPDE4APDE4BPDE4CDGAT1 | |
| SCHEMBL129027 | 0.92 | PDE4D (0.34) | PDE4DPDE4APDE4BPDE4CTLR7 | |
| SCHEMBL128072 | 0.92 | PDE4D (0.33) | PDE4DPDE4APDE4BPDE4CTLR7 | |
| SCHEMBL129618 | 0.92 | PDE4D (0.35) | PDE4DPDE4APDE4BPDE4CTLR7 | |
| SCHEMBL128818 | 0.91 | DGAT1 (0.32) | PDE4DPDE4APDE4BPDE4CDGAT1 | |
| SCHEMBL127425 | 0.91 | PDE4D (0.33) | PDE4DPDE4APDE4BPDE4CDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | PDE4D 3827/4885PDE4A 3035/4885PDE4B 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.